Skip to main content
Fig. 1 | World Journal of Surgical Oncology

Fig. 1

From: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy

Fig. 1

a PD-L1 immunohistochemical expression is 20% on the tumor and 10% on the TILs (×400, HPF). b PD-L1 immunohistochemical expression is 25% on the tumor and 20% on the TILs (×400, HPF). c PD-L1 immunohistochemical expression is 15% on the tumor and 20% on the TILs (×400, HPF). d 1-PD-L1 immunohistochemical expression on the tumor 2% and 10% on the TILs (×400, HPF)

Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us